Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Natasha B. Leighl, Naiyer A. Rizvi, Lopes Gilberto de Lima, Wichit Arpornwirat, Charles M. Rudin, Alberto A. Chiappori, Myung Ju Ahn, Laura Q M Chow, Lyudmila Bazhenova, Arunee Dechaphunkul, Patrapim Sunpaweravong, Keith Eaton, Jihong Chen, Sonja Medley, Srinivasu Poondru, Margaret Singh, Joyce Steinberg, Rosalyn A. Juergens, Shirish M. Gadgeel

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations'. Together they form a unique fingerprint.

Medicine & Life Sciences